Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Brain Research Année : 2008

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Yannick Marie
  • Fonction : Auteur
  • PersonId : 760117
  • IdRef : 186339437
Maryam Fourtassi
  • Fonction : Auteur
  • PersonId : 760122
  • IdRef : 202701263

Résumé

The transcription factor p53 and its negative regulator MDM2 are pivotal in normal and cancer cells biology. Recently, a functional single-nucleotide polymorphism in the promoter region of MDM2 (MDM2 SNP309), alone or in combination with TP53 R72P, was shown to be associated with the risk, prognosis, age at onset, molecular markers, and response to chemotherapy of various cancers. This SNP has never been specifically investigated in a large series of oligodendroglial tumors. In a comparison with 232 healthy controls, we retrospectively analyzed blood samples of 293 oligodendroglial tumor patients for MDM2 SNP309. In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial tumors, were investigated. The frequencies of T/T, T/G, and G/G genotypes in patients and controls did not suggest an increased risk of oligodendroglial tumor formation correlating with MDM2 SNP309. A borderline association was found between MDM2 SNP309 and overall survival (p=0.05), but in multivariate analysis, MDM2 SNP309 did not provide prognostic information complementary to age, tumor phenotype, grade, and 1p/19q status in oligodendroglial tumors. Finally, MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.

Domaines

Génétique

Dates et versions

inserm-00310504 , version 1 (10-08-2008)

Identifiants

Citer

Ahmed Idbaih, Blandine Boisselier, Yannick Marie, Marc Sanson, Soufiane El Hallani, et al.. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.. Brain Research, 2008, 1198, pp.16-20. ⟨10.1016/j.brainres.2008.01.027⟩. ⟨inserm-00310504⟩
105 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More